Unicycive Therapeutics, Inc.
Price Action
Technical Summary
EMERGING TRENDUnicycive Therapeutics, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 81), indicating clear outperformance against the broad market. Earnings growth of 28% provides fundamental context to the price action. Investors should exercise caution due to high volatility (94% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $6.48 | +6.99% | ABOVE |
| 50 SMA | $6.30 | +10.02% | ABOVE |
| 100 SMA | $5.81 | +19.24% | ABOVE |
| 150 SMA | $5.28 | +31.16% | ABOVE |
| 200 SMA | $5.42 | +27.83% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is UNCY in an uptrend right now?
UNCY has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is UNCY overbought or oversold?
UNCY's RSI (14) is 56. The stock is in neutral territory, neither overbought nor oversold.
Is UNCY outperforming the market?
UNCY has a Relative Strength (RS) Rating of 81 out of 99. Yes, UNCY is a market leader, outperforming 81% of all stocks over the past 12 months.
Where is UNCY in its 52-week range?
UNCY is trading at $6.93, which is 63% of its 52-week high ($11.00) and 44% above its 52-week low ($3.71).
How volatile is UNCY?
UNCY has a Beta of 0.81 and 52-week volatility of 94%. It's less volatile than the S&P 500 - generally more stable.